產(chǎn)品概述:
產(chǎn)品內(nèi)容
組分 |
S6011S (5-20 μg) |
S6011M (20-50 μg) |
S6011L (50-100 μg) |
A: Dye vial |
1 vial |
1 vial |
1 vial |
B: Super-n-stain® reaction buffer, 10 × |
1 vial of 15 μL |
1 vial of 15 μL |
1 vial of 30 μL |
C: Super-n-stain® antibody storage buffer |
1 vial of 60 μL |
1 vial of 150 μL |
1 vial of 300 μL |
D: Ultrafiltration vial (MWCO=10K) |
1 each |
1 each |
1 each |
染料信息
Super-n-stain® Antibody Labeling Kit |
貨號(hào) |
||||
Label Dye |
Ex (nm) |
Em (nm) |
1 × (5-20 μg) |
1 × (20-50 μg) |
1 × (50-100 μg) |
Biotin |
N/A |
N/A |
S601101S |
S601101M |
S601101L |
FITC |
494 |
518 |
S601102S |
S601102M |
S601102L |
YF®350 SE |
347 |
448 |
S601103S |
S601103M |
S601103L |
YF®405S SE |
404 |
431 |
S601104S |
S601104M |
S601104L |
LS405 SE |
408 |
452 |
S601105S |
S601105M |
S601105L |
YF®488(6)-2 SE |
490 |
515 |
S601106S |
S601106M |
S601106L |
YF®532 SE |
527 |
558 |
S601107S |
S601107M |
S601107L |
YF®555 SE |
555 |
565 |
S601121S |
S601121M |
S601121L |
YF®568 SE |
562 |
583 |
S601108S |
S601108M |
S601108L |
YF®594 SE |
590 |
617 |
S601109S |
S601109M |
S601109L |
YF®640 SE |
642 |
662 |
S601112S |
S601112M |
S601112L |
YF®647A SE |
650 |
665 |
S601113S |
S601113M |
S601113L |
YF®660 SE |
663 |
682 |
S601114S |
S601114M |
S601114L |
YF®750 SE |
750 |
777 |
S601120S |
S601120M |
S601120L |
儲(chǔ)存條件
-20℃保存,有效期見外包裝。
產(chǎn)品應(yīng)用
Super-n-stain® 抗體標(biāo)記試劑盒包含您需要的利用本公司YF 染料或生物素(Biotin)迅速標(biāo)記抗體的所有組分。標(biāo)記過程只需將抗體和染料簡單混合于試劑盒內(nèi)提供的反應(yīng)緩沖溶液中,進(jìn)行短時(shí)間的孵育即可。Super-n-stain® 染料在標(biāo)記結(jié)束時(shí)不再反應(yīng),因此無需進(jìn)一步純化步驟。標(biāo)記后,約4-6分子染料與1分子抗體共價(jià)結(jié)合。Super-n-stain®是共價(jià)標(biāo)記,所以用它標(biāo)記的抗體可以用于多色熒光染色,而不會(huì)發(fā)生抗體間的染料轉(zhuǎn)移現(xiàn)象。
Super-n-stain® 標(biāo)記可以兼容NaN3、低濃度的甘油、Tris和甘氨酸。試劑盒里提供的微型超濾離心管可以在標(biāo)記前快速去除不兼容的小分子抗體穩(wěn)定劑。標(biāo)準(zhǔn)Super-n-stain® 標(biāo)記步驟可以用于多于IgG (μg) 4倍的BSA或明膠樣品。根據(jù)您希望標(biāo)記的IgG量來選擇試劑盒大小。優(yōu)化標(biāo)記步驟適用于穩(wěn)定蛋白質(zhì)過剩或腹水的IgG樣品。在這種情況下,根據(jù)需要標(biāo)記抗體樣本的蛋白質(zhì)總量(IgG + 穩(wěn)定劑,或腹水中總蛋白量)來選擇試劑盒大小。優(yōu)化步驟也可用于標(biāo)記IgG量低于最低范圍的樣品,通過添加穩(wěn)定劑蛋白使總蛋白量達(dá)到試劑盒的標(biāo)記范圍。優(yōu)化步驟不建議用于標(biāo)記天然抗血清或雜交瘤細(xì)胞株培養(yǎng)上清,因?yàn)檫@些樣本的抗體含量相對于總蛋白非常低。
當(dāng)用熒光標(biāo)記抗體直接進(jìn)行免疫熒光時(shí),您可能需要使用更高濃度的抗體來實(shí)現(xiàn)類似間接免疫熒光法檢測(一抗加標(biāo)記二抗)染色的強(qiáng)度。在我們的內(nèi)部測試中發(fā)現(xiàn),間接免疫熒光染色結(jié)果是直接免疫熒光染色信號(hào)的三倍左右。
標(biāo)記二抗仍可以連接到使用Super-n-stain® 試劑盒標(biāo)記的一抗上,因此如果多個(gè)來自同一物種的抗體用于多色免疫熒光染色法,二抗無法區(qū)分同一物種來源的未標(biāo)記的一抗和使用Super-n-stain® 試劑盒標(biāo)記的一抗。Super-n-stain®標(biāo)記抗體可以用作傳統(tǒng)間接免疫熒光法檢測后的三級(jí)染色。UElandy 還提供生物素Super-n-stain® 標(biāo)記試劑盒、二次檢測使用的YF 染料標(biāo)記的鏈霉親和素或YF染料標(biāo)記的單克隆生物素抗體。
我們還提供酶標(biāo)記和熒光蛋白標(biāo)記的 Super-n-stain®試劑盒,以及小配體標(biāo)記試劑盒(請?jiān)L問www.yunmengxiang.com)。更多信息,請參見常見問題。
使用本產(chǎn)品的文獻(xiàn):
引用文獻(xiàn)
1.Paraoxonase 2 decreases renal reactive oxygen species production, lowers blood pressure, and mediates dopamine D2 receptor-induced inhibition of NADPH oxidase
應(yīng)用方向:polyclonal rabbit anti-PON2 antibody/ polyclonal rabbit anti-D2R antibody
2.The Q loops of the human multidrug resistance transporter ABCB1 are necessary to couple drug binding to the ATP catalytic cycle
應(yīng)用方向:Primary antibody 4E3
3.Increased Metabolite Levels of Glycolysis and Pentose Phosphate Pathway in Rabbit Atherosclerotic Arteries and Hypoxic Macrophage
應(yīng)用方向:anti-Ki-67 antibody/anti-macrophage antibody / anti-SMC antibody
4.Mucosal immunoglobulins at respiratory surfaces mark an ancient association that predates the emergence of tetrapods
應(yīng)用方向:rabbit anti-trout IgT / mouse anti-trout IgM / rabbit anti-Ich
5.Data ofrationalprocessoptimization for the production of a full IgG and its Fab fragment from hybridoma cells
應(yīng)用方向:IgG
6.Adenoviral L4 33K forms ring-like oligomers and stimulates ATPase activity of IVa2: implications in viral genome packaging
應(yīng)用方向:polyclonal anti-IVa2 and anti-33K antibodies
7.Principal cell activity induces spine relocation of adult-born interneurons in the olfactory bulb
應(yīng)用方向:Anti-synaptophysin antibody
8.Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma
應(yīng)用方向:anti-CD38 chitosan NPs